|
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
|
27 May 2021 |
|
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
|
15 April 2021 |
|
GSK to support manufacture of Novavax' COVID-19 vaccine
|
30 March 2021 |
|
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
|
24 February 2021 |
|
GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses
|
19 February 2021 |
|
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
|
04 February 2021 |
|
Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
|
15 January 2021 |
|
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
|
17 December 2020 |
|
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly
|
11 December 2020 |
|
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
|
12 November 2020 |